Allos Therapeutics Inc - Current report filing (8-K)
08 1월 2008 - 6:47AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 7, 2008 (January 7, 2008)
ALLOS
THERAPEUTICS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On January 7, 2008,
Allos Therapeutics, Inc., a Delaware
corporation (the Company), issued a
press release announcing the initiation of patient enrollment in a Phase
2b, randomized, multi-center study comparing PDX (pralatrexate) and Tarceva ®
(erlotinib) in patients with Stage IIIB/IV non-small cell lung cancer (NSCLC)
who are, or have been, cigarette smokers who have failed treatment with at least
one prior platinum-based chemotherapy regimen.
The press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
99.1
|
Press
Release, dated January 7, 2008, entitled Allos Therapeutics Initiates Phase 2b Study of PDX in Patients with
Non-small Cell Lung Cancer.
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 7, 2008
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
David C. Clark
|
|
|
David
C. Clark
|
|
Its:
|
Vice
President, Finance and Treasurer
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated January 7, 2008, entitled Allos Therapeutics Initiates Phase 2b Study of PDX in Patients with
Non-small Cell Lung Cancer.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics Inc News Articles